APA (7th ed.) Citation

Uehara, Y., Takeyasu, Y., Yoshida, T., Tateishi, A., Torasawa, M., Hosomi, Y., . . . Ohe, Y. Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC. Elsevier.

Chicago Style (17th ed.) Citation

Uehara, Y., et al. Real-world Outcomes of Treatment Strategy Between First-line Osimertinib, First/second-generation EGFR-TKIs Followed by Osimertinib and Without Osimertinib in Advanced EGFR-mutant NSCLC. Elsevier.

MLA (9th ed.) Citation

Uehara, Y., et al. Real-world Outcomes of Treatment Strategy Between First-line Osimertinib, First/second-generation EGFR-TKIs Followed by Osimertinib and Without Osimertinib in Advanced EGFR-mutant NSCLC. Elsevier.